# Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma

> **NCT03024489** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Mahidol University** · enrollment: 27 (actual)

## Conditions studied

- Head and Neck Cancer
- Locally Advanced

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Palbociclib
- **DRUG:** Palbociclib
- **DRUG:** Palbociclib
- **DRUG:** Cetuximab
- **RADIATION:** Intensity Modulated Radiation Therapy

## Key facts

- **NCT ID:** NCT03024489
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-19
- **Primary completion:** 2024-03-11
- **Final completion:** 2024-12-31
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03024489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03024489, "Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03024489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*